Nanalysis Scientific Corp. reports developments tied to portable Nuclear Magnetic Resonance spectrometers, MRI and imaging technology, and related services for industrial and research applications. Company updates describe instruments used in pharmaceutical, biotech, energy, food, materials, security, academic, and government settings, as well as a services division that maintains Nanalysis products and third-party imaging equipment.
Recurring news themes include quarterly and annual results, conference-call announcements, supply-chain and market-diversification updates, non-dilutive funding, private placement financings, equity incentive grants, and board composition changes. The company also references its long-term Canadian Air Transport Security Authority relationship for security-scanner maintenance at Canadian airports.
Nanalysis (OTC: NSCIF) announced on March 4, 2026 that its Board granted 1,210,000 restricted share units (RSUs) and 350,000 stock options to certain directors, officers and employees under its equity plans. Each option is exercisable for one common share at $0.20 per share for five years. Each vested RSU entitles the holder to one common share.
Nanalysis (OTCQX: NSCIF, TSXV: NSCI) closed the second and final tranche of its $3.4 million non‑brokered private placement on Jan 26, 2026. The Second Tranche issued 6,145,300 units at $0.15 per unit for gross proceeds of $921,795, bringing the Offering total to 22,671,583 units. Each unit includes one share and one‑half warrant; each whole warrant allows purchase of one share at $0.20 until two years from closing, subject to acceleration if the share price trades at $0.30 for 10 consecutive trading days. The company paid $2,000 in finder’s fees to Leede Financial and securities remain subject to a statutory hold period of four months plus one day. TSX Venture final acceptance is pending.
Nanalysis (OTCQX: NSCIF) closed the first tranche of a non‑brokered private placement on Dec 23, 2025, issuing 16,526,283 Units at $0.15 each for gross proceeds of about $2.5M. Each Unit includes one share and one‑half warrant; each full warrant is exercisable at $0.20 until two years from closing with acceleration if the share price trades at $0.30 for 10 consecutive days. The company upsized the Offering to allow issuance of up to an additional 23,333,333 Units for up to $3.5M, subject to TSX Venture Exchange approval. Net proceeds are earmarked for debt reduction and magnet inventory purchases; securities issued carry a statutory four‑month plus one‑day hold.
Nanalysis (OTCQX: NSCIF) announced a non-brokered private placement of up to 16,666,667 Units at $0.15 per Unit to raise up to $2,500,000 in gross proceeds. Each Unit comprises one common share and one-half of one warrant; the 8,333,333 whole Warrants will be exercisable at $0.20 per share until two years from closing and include an acceleration clause if the share price trades at $0.30 for 10 consecutive trading days. Net proceeds are designated for debt reduction. Closing is subject to TSX Venture Exchange acceptance, may occur in tranches, and an initial close is anticipated on or about December 15, 2025. Securities will carry a statutory hold period of four months and one day.
Nanalysis Scientific Corp. (OTCQX: NSCIF) reported Q3 2025 consolidated revenue of $9,285K, down 12% year-over-year, and nine-month revenue of $29,455K, down 11% year-over-year. Product sales declined sharply: $2,719K in Q3 (-36% YoY) and $9,308K YTD (-33% YoY). Security services revenue grew: Q3 $5,943K (+10% YoY) and YTD $16,583K (+8% YoY). Q3 product gross margin fell to 44% from 52%, while nine-month product margin improved to 58% from 50%. Adjusted EBITDA was ($2K) for Q3 and ($284K) YTD. Net loss improved to ($1,500K) in Q3 and ($4,929K) YTD. The company executed a five-year OEM and licensing agreement with IMRIS, resolved magnet supply constraints, and is restructuring its sales organization to refocus on benchtop NMR sales.
Pintec (Nasdaq: PT) reported unaudited results for the six months ended June 30, 2025: revenues RMB15.33M (+2.71% YoY), gross profit RMB9.34M (gross margin 60.92%), and net loss RMB4.73M (down 43.26% YoY). Loan facilitation and outstanding balances declined (loans facilitated RMB40.17M, outstanding RMB53.13M).
The company had cash and long-term restricted cash RMB38.90M, negative working capital of RMB403.79M, and an accumulated deficit of RMB2,533.38M. Pintec obtained a US$40M credit line and completed a share-based transaction to consolidate ZIITECH.
Nanalysis (OTCQX: NSCIF) announced a management change: Randall McRae will resign as Chief Financial Officer effective December 5, 2025 and will remain available to the company in an advisory capacity after his departure.
Heather Kury, Corporate Controller, will be appointed Interim Chief Financial Officer while the board searches for a permanent successor. Ms. Kury is a CPA, CA with over 20 years' experience, holds a Bachelor of Arts (Accounting and History) from the University of Winnipeg, and is a member of the Institute of Chartered Professional Accountants of Alberta.
Nanalysis (OTCQX: NSCIF) announced native file support for its portable NMR instruments in Wiley KnowItAll 2026, enabling direct import of raw low-field NMR files into KnowItAll and two-way workflow integration.
The update lets KnowItAll users run low-field NMR analysis inside a multi‑technique platform and lets Nanalysis users access KnowItAll’s processing, prediction, searching and Wiley’s spectral libraries, which contain over 1.28 million 1D spectra across 1H, 13C and multiple X‑NMR nuclei. Subscription required for some libraries.
Nanalysis Scientific Corp. (OTCQX: NSCIF) has secured a significant five-year OEM supplier and technology licensing agreement with IMRIS Imaging, Inc., a leader in intraoperative MRI. The non-exclusive agreement includes an upfront payment and builds upon a previous 12-month contract.
The partnership leverages Nanalysis's core electronics and software technology platform, which is utilized across their benchtop NMR, high-field NMR, and MRI products. IMRIS has validated Nanalysis's MRI console during system prototyping, positioning the company as a critical component supplier for IMRIS's integrated operating suites.
Nanalysis Scientific Corp. (OTCQX: NSCIF) reported challenging Q2 2025 results marked by a 17% decline in total revenue to $9.6 million. Product sales dropped significantly by 46% to $2.9 million, while security services revenue increased by 7% to $5.6 million.
Despite revenue challenges, the company achieved notable improvements in product sales gross margins, increasing to 61% from 50% year-over-year. The company reported an Adjusted EBITDA loss of $462,000 compared to a profit of $759,000 in Q2 2024, and a net loss of $2.1 million.
Key developments include closing a $2 million promissory note financing, implementing efficiency measures in security services, and securing loan amendments to reduce principal payments through April 2026.